Showing results (11-20 of 250) with videos related to
Sort By:
Pageof 25
Pediatric Clinics of North America|November 28, 2017
Therapeutic Drug Monitoring in Inflammatory Bowel Disease: History and Future DirectionsElizabeth A Spencer, Marla C DubinskyCurrent Treatment Options in Gastroenterology|May 15, 2003
Treatment of Crohn's Disease of Inflammatory, Stenotic, and Fistulizing PhenotypesMarla C. Dubinsky, Phillip P. FleshnerCurrent Gastroenterology Reports|May 26, 2009
Probiotics in pediatric inflammatory bowel diseasesAjay S Gulati, Marla C DubinskyJournal of Clinical Pharmacology|February 25, 2015
Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodiesDiane R Mould, Marla C DubinskyInflammatory Bowel Diseases|June 8, 2017
Fecal Calprotectin Levels Predict Histological Healing in Ulcerative ColitisAnish Patel, Hinaben Panchal, Marla C DubinskyInflammatory Bowel Diseases|February 21, 2014
A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel diseaseElaheh Vahabnezhad, Shervin Rabizadeh, Marla C DubinskyGastrointestinal Endoscopy Clinics of North America|September 17, 2016
The First Endoscopy in Suspected Inflammatory Bowel DiseaseRebecca A Fausel, Asher Kornbluth, Marla C DubinskyAlimentary Pharmacology & Therapeutics|August 22, 2022
Review article: guide to tofacitinib dosing in patients with ulcerative colitisPeter M Irving, Yvette Leung, Marla C DubinskyInflammatory Bowel Diseases|June 20, 2018
The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBDElizabeth Spencer, Evan Norris, Chadwick Williams, et al.Inflammatory Bowel Diseases|July 23, 2013
Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel diseaseParambir S Dulai, Corey A Siegel, Marla C DubinskyPageof 25